An interventional program composed of physical activity and psychological support may help improve fatigue levels in myasthenia gravis patients, a…
Patricia Inacio, PhD
Science Writer
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
Education
- PhD in Cell Biology, University Nova de Lisboa, Portugal, 2013
- MSc in Biology, 2007
Published Works
- van Tienderen GS, (…), Inacio, P. et al, Cancer Cell. 2022 Mar 14;40(3):226-230.
- Inacio, P. et al, Gut. 2019 Dec;68(12):2228-2237.
- Inacio, P. et al, EMBO Rep. 2015 Aug;16(8):955-64.
- Pinheiro, H (…), Inacio, P. et al, Hum Mol Genet. 2010 Mar 1;19(5):943-52.
Professional Accomplishments
- 2012, Scholarship from Luso-American Development Foundation (Portugal/USA) to perform research at Columbia University, New York
- 2007, Winner of the 1st prize of “Grant Proposal” Final Exercise of Gulbenkian PhD Program
- 2007, PhD Scholarship from Fundação para a Ciência e Tecnologia (Portugal)
- 2007, Selected for the International Gulbenkian PhD Program, at Instituto Gulbenkian de Ciência (IGC), Lisbon, Portugal
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
A small but significant percentage of myasthenia gravis (MG) patients remain resistant to current therapies, which severely impacts on…
Between 30 percent and 50 percent of all thymoma patients – people treated for a tumor in the thymus gland…
Careful patient assessment and planning prior to surgery was needed to successfully remove a tumor from the thymus of a myasthenia…
Ra Pharma’s RA101495, a potential treatment for generalized myasthenia gravis patients, showed preliminary signs of halting red blood cell destruction…
Myasthenia gravis patients appear to have lower levels of vitamin D than the general population, a study confirmed. The confirmation…
Blood levels of a microRNA called miR-150-5p have been identified as a potential biomarker for AChR-positive myasthenia gravis, after surgical…
Using robotic-assisted surgery to remove the thymus without putting a patient on an immunosuppressant afterwards leads to higher myasthenia gravis (MG) improvement…
Ra Pharmaceuticals, which is now enrolling patients with generalized myasthenia gravis into a Phase 2 clinical trial, joined millions…
Researchers in Japan wrote about a new case study where treatment with the immunotherapy Opdivo (nivolumab) led to a…